Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
Blood (2022) 140 (Supplement 1): 1467–1470.
Currently there are no citedby results. Try again later.
